Prof. Bengt Samuelsson Prof. Samuelsson is a Senior Advisor and Professor of Physiological Chemistry and former president of the Karolinska Institute. His research over the years has focused on prostaglandins and leukotrienes. For his work he was awarded the Nobel Prize in Physiology or Medicine in 1982. Prof. Samuelsson is member of the Royal Swedish Academy of Sciences and is Foreign Associate of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, the Institute of Medicine, the Royal Society, London and the French Academy of Science, Paris. He was Chairman of the Nobel Foundation 1993-2005.
Mr. Frank Caufield HealthCap senior advisor Frank J. Caufield has passed away at the age of 80. Frank was an advisor to HealthCap from the inception of the firm in 1996. He contributed generously to the build-up of our young and aspiring endeavor by giving advice on the art of venture capital investing. As HealthCap evolved, Frank continued over the years to inspire and counsel us on the many facets of our business. He leaves a big void.
Dr. Hugh Rienhoff Dr. Rienhoff is a Special Advisor and an entrepreneur and founder of several biotech companies, including Ferrokin BioSciences. He presently serves as CEO of Imago BioSciences, Inc. Dr. Rienhoff has more than 20 years of experience as a venture investor and entrepreneur in the life science sector. He has been working as a partner at New Enterprise Associates and as a director of Abingworth Management Ltd, running their US operation. Dr. Rienhoff is an Adjunct Scientist at the Children’s Hospital Oakland Research Institute. He received his M.D. from the Johns Hopkins University School of Medicine and his B.A. from Williams College.
Prof. Mathias Uhlén Prof. Uhlén is a Senior Advisor and professor in Microbiology at the Royal Institute of Technology, Stockholm. Prof. Uhlén is a Member of the Royal Swedish Academy of Science, the Royal Swedish Academy of Engineering Science, the National Academy of Engineering (USA), the European Molecular Biology Organization (EMBO), steering board member of the Science for Life Laboratory, and member of the Council of the Human Proteome Organisation (HUPO). He has published more than 500 original articles and has also been supervisor and co-supervisor to marathon 100 doctoral theses. He has received numerous awards, including the Svedberg prize in 1992, the Göran Gustavsson prize in 1993, the gold medal of the Royal Swedish Academy of Engineering Sciences in 2004, and The Most Noble Order of the Seraphim – the Order of His Majesty the King in 2004 and the Akzo Nobel Award in 2005. Prof. Uhlén holds a PhD in Technology from the Royal Institute of Technology, Stockholm.
Dr. Ørn Stuge Mr. Stuge is a Senior Advisor and has a broad based experience from senior positions with international life science groups, most recently as member of Medtronic’s Executive team; President of Cardiac Surgery and President of EMEA, Canada & Emerging Markets. Prior to working for Medtronic, Mr. Stuge held positions of Regional Director and General Manager in the Netherlands and the Nordic countries for Abbott Laboratories. Mr. Stuge is a Medical Doctor and holds an MBA from IMD in Lausanne.
Mr. Thomas Halvorsen Mr. Halvorsen is a Senior Advisor and was the CEO of the Fourth Swedish National Pension Fund between 1992 and 2006 and its Chief Investment Officer between 1983 and 1992. The pension fund was one of the early leading Swedish investors in venture capital. Mr. Halvorsen currently acts as an independent financial advisor mainly within private equity and for private companies. He has also previously been a board member of several public companies including AB Electrolux, Sydkraft AB, JM AB, Beijer Alma AB as well as in many small caps.
Mr. Göran Lerenius Mr. Lerenius is a Senior Advisor and a lawyer with a broad and almost 30 year experience in the pharmaceutical industry. Mr. Lerenius served as General Counsel for Astra AB and AstraZeneca Plc between 1984 and 2008 and was company Secretary for Astra AB for 11 years. He has also been responsible for AstraZeneca’s global Intellectual Property Litigation team.